Pfizer, Merck Reach $2.9B Deal To Develop Cancer Drug
Pfizer Inc. has reached an up to $2.9 billion deal with Germany's Merck KGaA to jointly develop a new cancer drug, the companies said Monday, bolstering Pfizer's cancer portfolio after it...To view the full article, register now.
Already a subscriber? Click here to view full article